RU2008116931A - Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей - Google Patents
Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей Download PDFInfo
- Publication number
- RU2008116931A RU2008116931A RU2008116931/14A RU2008116931A RU2008116931A RU 2008116931 A RU2008116931 A RU 2008116931A RU 2008116931/14 A RU2008116931/14 A RU 2008116931/14A RU 2008116931 A RU2008116931 A RU 2008116931A RU 2008116931 A RU2008116931 A RU 2008116931A
- Authority
- RU
- Russia
- Prior art keywords
- desmethylclozapine
- psychosis
- subject
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Способ улучшения состояния при психозе любого происхождения, с одновременным увеличением уровня активности мускаринового рецептора, включающий введение субъекту, нуждающемуся в этом, терапевтически эффективное количество N-десметилклозапина. ! 2. Способ по п.1, в котором субъект является человеком. ! 3. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде единичной дозы. ! 4. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде многократных доз. ! 5. Способ по п.1, в котором психоз ассоциирован с шизофренией. ! 6. Способ по п.1, в котором психоз ассоциирован с болезнью Альцгеймера. ! 7. Способ по п.1, в котором введение N-десметилклозапина дополнительно улучшает состояние при когнитивном нарушении любого происхождения. ! 8. Способ по п.1, включающий введение субъекту фармацевтической композиции, включающей N-десметилклозапин и фармацевтически приемлемый разбавитель или эксципиент. ! 9. Способ по п.8, в котором фармацевтическая композиция включает от 0,01 до 1000 мг N-десметилклозапина. ! 10. Способ по п.1, где мускариновый рецептор представляет собой рецептор М1.
Claims (10)
1. Способ улучшения состояния при психозе любого происхождения, с одновременным увеличением уровня активности мускаринового рецептора, включающий введение субъекту, нуждающемуся в этом, терапевтически эффективное количество N-десметилклозапина.
2. Способ по п.1, в котором субъект является человеком.
3. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде единичной дозы.
4. Способ по п.1, в котором терапевтически эффективное количество N-десметилклозапина вводят в виде многократных доз.
5. Способ по п.1, в котором психоз ассоциирован с шизофренией.
6. Способ по п.1, в котором психоз ассоциирован с болезнью Альцгеймера.
7. Способ по п.1, в котором введение N-десметилклозапина дополнительно улучшает состояние при когнитивном нарушении любого происхождения.
8. Способ по п.1, включающий введение субъекту фармацевтической композиции, включающей N-десметилклозапин и фармацевтически приемлемый разбавитель или эксципиент.
9. Способ по п.8, в котором фармацевтическая композиция включает от 0,01 до 1000 мг N-десметилклозапина.
10. Способ по п.1, где мускариновый рецептор представляет собой рецептор М1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44269003P | 2003-01-23 | 2003-01-23 | |
| US60/442,690 | 2003-01-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005126614/15A Division RU2336879C2 (ru) | 2003-01-23 | 2004-01-21 | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008116931A true RU2008116931A (ru) | 2009-11-10 |
Family
ID=32772052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005126614/15A RU2336879C2 (ru) | 2003-01-23 | 2004-01-21 | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей |
| RU2008116931/14A RU2008116931A (ru) | 2003-01-23 | 2008-04-28 | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005126614/15A RU2336879C2 (ru) | 2003-01-23 | 2004-01-21 | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20040224942A1 (ru) |
| EP (2) | EP1994932A1 (ru) |
| JP (1) | JP2006515628A (ru) |
| KR (1) | KR20050092123A (ru) |
| CN (1) | CN1741803A (ru) |
| AU (1) | AU2004206931A1 (ru) |
| BR (1) | BRPI0406592A (ru) |
| CA (1) | CA2512043A1 (ru) |
| MX (1) | MXPA05007784A (ru) |
| NZ (1) | NZ541014A (ru) |
| RU (2) | RU2336879C2 (ru) |
| SG (1) | SG159390A1 (ru) |
| WO (1) | WO2004064753A2 (ru) |
| ZA (1) | ZA200505878B (ru) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1263729B1 (en) | 2000-03-06 | 2006-12-20 | Acadia Pharmaceuticals Inc. | Azacyclic compounds for use in the treatment of serotonin related diseases |
| RU2315051C2 (ru) | 2001-12-28 | 2008-01-20 | Акадиа Фармасьютикалз, Инк. | Спироазациклические соединения, способ ингибирования активности или активации серотонинового 5-нт2а рецептора, способ лечения болезненного состояния, связанного с серотониновым 5-нт2а рецептором, и их применение |
| BR0312217A (pt) | 2002-06-24 | 2005-05-10 | Acadia Pharm Inc | Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| CN1816524B (zh) | 2003-01-16 | 2012-06-27 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| KR20050092123A (ko) * | 2003-01-23 | 2005-09-20 | 아카디아 파마슈티칼스 인코포레이티드 | Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도 |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| WO2004073639A2 (en) * | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| US20060217365A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating mood disorders |
| US20060252743A1 (en) * | 2005-01-07 | 2006-11-09 | Astrazeneca Ab | Method of treating sleep disorders |
| US20090093460A1 (en) * | 2003-07-02 | 2009-04-09 | Astrazeneca Ab | Compositions |
| US20060217367A1 (en) * | 2004-07-01 | 2006-09-28 | Astrazeneca Ab | Method of treating anxiety disorders |
| US20090093461A1 (en) * | 2003-07-02 | 2009-04-09 | Astrazeneca Ab | Methods of Treating Anxiety and Mood Disorders |
| ES2349091T3 (es) * | 2003-07-02 | 2010-12-27 | Astrazeneca Ab | Metabolito de quetiapina. |
| US20070117789A1 (en) * | 2005-11-18 | 2007-05-24 | Astrazeneca Ab | Method of treatment |
| US20060229292A1 (en) * | 2005-01-07 | 2006-10-12 | Astrazeneca Ab | Method of treating childhood disorders |
| US20060217366A1 (en) * | 2003-07-02 | 2006-09-28 | Astrazeneca Ab | Method of treating schizophrenia and other disorders |
| KR101157881B1 (ko) * | 2003-12-22 | 2012-07-06 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 작용제로서의 아미노 치환된 디아릴［ａ,ｄ］사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법 |
| US20090239840A1 (en) * | 2003-12-22 | 2009-09-24 | Acadia Pharmaceuticals, Inc. | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| KR20070007888A (ko) * | 2004-04-01 | 2007-01-16 | 아카디아 파마슈티칼스 인코포레이티드 | 결정질 ｎ-데스메틸클로자핀 |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| JP2008509147A (ja) * | 2004-08-05 | 2008-03-27 | アカディア ファーマシューティカルズ，インコーポレーテッド | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 |
| NZ553702A (en) | 2004-09-27 | 2010-10-29 | Acadia Pharm Inc | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| US20060252744A1 (en) * | 2005-04-04 | 2006-11-09 | Burstein Ethan S | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| EP2275095A3 (en) * | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US20070105836A1 (en) * | 2005-10-31 | 2007-05-10 | Lars Pettersson | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
| ES2365897T3 (es) | 2006-06-22 | 2011-10-13 | Ramot, At Tel Aviv University Ltd. | Nuevos inhibidores de la recaptación de serotonina como fármacos que tienen actividad limitada al sistema periférico. |
| US9278947B2 (en) | 2006-06-22 | 2016-03-08 | Ramot At Tel-Aviv University Ltd. | Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity |
| ES2423485T3 (es) | 2007-03-19 | 2013-09-20 | Acadia Pharmaceuticals Inc. | Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos |
| CN102131791B (zh) * | 2008-06-20 | 2014-12-24 | 阿斯利康(瑞典)有限公司 | 二苯并硫杂氮杂*衍生物及其用途 |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| RU2506073C1 (ru) * | 2012-09-06 | 2014-02-10 | Алексей Николаевич Паршин | Способ лечения расстройства адаптации у пациентов с суицидальным риском |
| WO2016109679A1 (en) * | 2014-12-31 | 2016-07-07 | Markovitz M D Ph D Paul | Method of treating schizophrenia |
| JP6850282B2 (ja) | 2015-07-20 | 2021-03-31 | アカディア ファーマシューティカルズ インコーポレーテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドならびにその酒石酸塩および多形形態ｃを調製する方法 |
| WO2017117347A1 (en) * | 2015-12-30 | 2017-07-06 | Markovitz M D Paul | Method of treating schizophrenia |
| RU2667954C2 (ru) * | 2016-03-04 | 2018-09-25 | Общество С Ограниченной Ответственностью "Валентек" | Фармацевтическая композиция для лечения функциональных психических расстройств |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US11464768B2 (en) | 2016-12-20 | 2022-10-11 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN107970243B (zh) * | 2017-10-30 | 2020-07-28 | 江苏理工学院 | 一种去甲氯氮平的新用途 |
| CN109761826B (zh) * | 2019-01-17 | 2022-02-25 | 烟台大学 | 一种o-去甲基文拉法辛苯醚化合物及其制备方法和用途 |
| CN114206349A (zh) | 2019-04-17 | 2022-03-18 | 指南针探路者有限公司 | 治疗神经认知障碍、慢性疼痛及减轻炎症的方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL140242B (nl) * | 1963-03-01 | 1973-11-15 | Wander Ag Dr A | Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen. |
| US3389139A (en) * | 1963-06-14 | 1968-06-18 | Wander Ag Dr A | 6-homopiperazino and piperazinomorphanthridines |
| US3908010A (en) * | 1967-03-22 | 1975-09-23 | Wander Ag Dr A | Basically substituted heterocycles as anti-emetics |
| US3884920A (en) * | 1967-07-14 | 1975-05-20 | Sandoz Ag | 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines |
| US3412193A (en) * | 1965-12-13 | 1968-11-19 | American Cyanamid Co | 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility |
| AT278805B (de) * | 1966-01-17 | 1970-02-10 | American Cyanamid Co | Verfahren zur herstellung von oxazepinen und thiazepinen |
| GB1184251A (en) * | 1966-04-15 | 1970-03-11 | American Cyanamid Co | Oxazepines and Thiazepines |
| GB1192812A (en) * | 1966-05-20 | 1970-05-20 | American Cyanamid Co | 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts |
| US3852446A (en) * | 1967-03-13 | 1974-12-03 | Sandoz Ag | Organic compounds in treatment of psychotic disturbances |
| US3539573A (en) * | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| US3758479A (en) * | 1967-03-22 | 1973-09-11 | Sandoz Ag | Nitro and sulphamoyl substituted dibenzodiazepines |
| US3751415A (en) * | 1967-03-22 | 1973-08-07 | Sandoz Ag | 2-nitro-11-(1-piperazinyl)-dibenz(b,f)(1,4)oxazepines |
| CA918659A (en) * | 1969-07-31 | 1973-01-09 | Yoshitomi Pharmaceutical Industries | 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines |
| US3660406A (en) * | 1970-10-26 | 1972-05-02 | American Cyanamid Co | 2-chloro-7-hydroxy-11-(1-piperazinyl)dibenz(b f)(1 4)oxazepines |
| CH555856A (de) * | 1971-05-04 | 1974-11-15 | Hoffmann La Roche | Verfahren zur herstellung von tricyclischen verbindungen. |
| US3962248A (en) * | 1972-04-04 | 1976-06-08 | Sandoz, Inc. | Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines |
| US3884446A (en) * | 1973-12-10 | 1975-05-20 | Dahl Co G W | Low profile control valve actuator |
| US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| US4045445A (en) * | 1975-12-14 | 1977-08-30 | American Cyanamid Company | 11-(4-Piperidyl)dibenzo-diazepines |
| CH624682A5 (ru) * | 1976-11-10 | 1981-08-14 | Sandoz Ag | |
| US4406900A (en) * | 1976-11-10 | 1983-09-27 | Sandoz Ltd. | Neuroleptic use of morphanthridines |
| US4191760A (en) * | 1977-02-23 | 1980-03-04 | Abbott Laboratories | Dibenzodiazepines |
| US4097597A (en) * | 1977-02-23 | 1978-06-27 | Abbott Laboratories | Dibenzo b,e! 1,4!diazepines |
| US4096261A (en) * | 1977-02-23 | 1978-06-20 | Abbott Laboratories | Dibenzodiazepines |
| CS196893B1 (en) * | 1977-12-22 | 1980-04-30 | Miroslav Protiva | 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines |
| US4263207A (en) * | 1978-08-01 | 1981-04-21 | Merck & Co., Inc. | 10,11-Dihydrodibenzo[b,f][1,4]thiazepine carboxylic acids esters and amides thereof |
| US4268207A (en) * | 1979-07-06 | 1981-05-19 | Eaton Corporation | Load support and shuttle |
| US4404137A (en) * | 1979-10-16 | 1983-09-13 | Lilly Industries Limited | Pyrazolo [3,4-b][1,5]benzodiazepine compounds |
| CH641876A5 (de) * | 1980-02-14 | 1984-03-15 | Sulzer Ag | Kolbenkompressor, insbesondere zum verdichten von sauerstoff. |
| US4764616A (en) * | 1983-05-18 | 1988-08-16 | Hoechst-Roussel Pharmaceuticals Inc. | Benzopyrrolobenzodiazepines and quinobenzodiazepines |
| US4663453A (en) * | 1983-05-18 | 1987-05-05 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity |
| JPH04211071A (ja) * | 1990-03-05 | 1992-08-03 | Hokuriku Seiyaku Co Ltd | 多環式化合物 |
| US5817655A (en) * | 1991-04-23 | 1998-10-06 | Eli Lilly And Company | Methods of treatment using a thieno-benzodiazepine |
| US5300422A (en) * | 1991-12-04 | 1994-04-05 | Case Western Reserve University | Screening method for controlling agranulocytosis |
| US5393752A (en) * | 1992-05-26 | 1995-02-28 | Therabel Research S.A./N.V. | Methylpiperazinoazepine compounds, preparation and use thereof |
| AU6913994A (en) * | 1993-05-13 | 1994-12-12 | New York University | Psychosis protecting nucleic acid, peptides, compositions and method of use |
| US5354747A (en) * | 1993-06-16 | 1994-10-11 | G. D. Searle & Co. | 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
| US5707798A (en) * | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
| US5538965A (en) * | 1993-12-23 | 1996-07-23 | Allelix Biopharmaceuticals Inc. | Dopamine receptor ligands |
| US6566065B1 (en) * | 1994-05-26 | 2003-05-20 | Mcgill University | Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene |
| US5602120A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Benzyl-substituted compounds having dopamine receptor affinity |
| US5602121A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | Alkyl-substituted compounds having dopamine receptor affinity |
| US5700445A (en) * | 1994-12-12 | 1997-12-23 | Allelix Biopharmaceuticals, Inc. | N-methyl piperazine compounds having dopamine receptor affinity |
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| GB9617305D0 (en) * | 1996-08-17 | 1996-09-25 | Glaxo Wellcome Spa | Heterocyclic compounds |
| ATE290000T1 (de) * | 2000-04-28 | 2005-03-15 | Acadia Pharm Inc | Muscarinagonisten |
| AU2002249885A1 (en) * | 2000-11-17 | 2002-08-12 | Adolor Corporation | Delta agonist analgesics |
| BR0314108A (pt) * | 2002-09-18 | 2006-04-25 | Fmc Corp | derivados tricìclios inseticidas |
| BR0317528A (pt) * | 2002-12-20 | 2005-11-22 | Basf Ag | Uso dos compostos, métodos para o controle de insetos, aracnìdeos ou nematodos, e para a proteção de plantas em crescimento contra o ataque ou a infestação por insetos, aracnìdeos ou nematodos, compostos, e, composições |
| CN1816524B (zh) * | 2003-01-16 | 2012-06-27 | 阿卡蒂亚药品公司 | 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂 |
| US20050085463A1 (en) * | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20070275957A1 (en) * | 2003-01-23 | 2007-11-29 | Weiner David M | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| KR20050092123A (ko) * | 2003-01-23 | 2005-09-20 | 아카디아 파마슈티칼스 인코포레이티드 | Ｎ-데스메틸클로자핀의 인간의 신경정신성 질환의 치료용도 |
| US20050250767A1 (en) * | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| WO2004073639A2 (en) * | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| KR101157881B1 (ko) * | 2003-12-22 | 2012-07-06 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 작용제로서의 아미노 치환된 디아릴［ａ,ｄ］사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법 |
| KR20070007888A (ko) * | 2004-04-01 | 2007-01-16 | 아카디아 파마슈티칼스 인코포레이티드 | 결정질 ｎ-데스메틸클로자핀 |
| DK1804804T3 (da) * | 2004-09-21 | 2012-02-20 | Hypnion Inc | 3-[4-(dibenzo[b,f][1,4]oxazepin-11-yl)-piperazin-1-yl]-2,2-dimethylpropansyre til anvendelse ved behandlingen af søvnforstyrrelser |
| US20060063754A1 (en) * | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| US20060252744A1 (en) * | 2005-04-04 | 2006-11-09 | Burstein Ethan S | Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents |
| US20070105836A1 (en) * | 2005-10-31 | 2007-05-10 | Lars Pettersson | Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders |
-
2004
- 2004-01-21 KR KR1020057013323A patent/KR20050092123A/ko not_active Application Discontinuation
- 2004-01-21 BR BR0406592-1A patent/BRPI0406592A/pt not_active IP Right Cessation
- 2004-01-21 NZ NZ541014A patent/NZ541014A/en unknown
- 2004-01-21 MX MXPA05007784A patent/MXPA05007784A/es not_active Application Discontinuation
- 2004-01-21 EP EP08016004A patent/EP1994932A1/en not_active Withdrawn
- 2004-01-21 SG SG200705214-5A patent/SG159390A1/en unknown
- 2004-01-21 CN CNA200480002642XA patent/CN1741803A/zh active Pending
- 2004-01-21 AU AU2004206931A patent/AU2004206931A1/en not_active Abandoned
- 2004-01-21 EP EP04704073A patent/EP1589974A2/en not_active Ceased
- 2004-01-21 CA CA002512043A patent/CA2512043A1/en not_active Abandoned
- 2004-01-21 JP JP2006501063A patent/JP2006515628A/ja not_active Withdrawn
- 2004-01-21 US US10/761,787 patent/US20040224942A1/en not_active Abandoned
- 2004-01-21 WO PCT/US2004/001509 patent/WO2004064753A2/en active Application Filing
- 2004-01-21 RU RU2005126614/15A patent/RU2336879C2/ru not_active IP Right Cessation
-
2005
- 2005-07-21 ZA ZA200505878A patent/ZA200505878B/en unknown
-
2008
- 2008-04-28 RU RU2008116931/14A patent/RU2008116931A/ru not_active Application Discontinuation
- 2008-09-22 US US12/235,526 patent/US20090018119A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1994932A1 (en) | 2008-11-26 |
| WO2004064753A3 (en) | 2004-11-25 |
| RU2005126614A (ru) | 2006-01-27 |
| ZA200505878B (en) | 2006-04-26 |
| WO2004064753A2 (en) | 2004-08-05 |
| US20090018119A1 (en) | 2009-01-15 |
| CA2512043A1 (en) | 2004-08-05 |
| KR20050092123A (ko) | 2005-09-20 |
| CN1741803A (zh) | 2006-03-01 |
| SG159390A1 (en) | 2010-03-30 |
| BRPI0406592A (pt) | 2005-12-20 |
| MXPA05007784A (es) | 2005-09-30 |
| US20040224942A1 (en) | 2004-11-11 |
| JP2006515628A (ja) | 2006-06-01 |
| EP1589974A2 (en) | 2005-11-02 |
| RU2336879C2 (ru) | 2008-10-27 |
| NZ541014A (en) | 2008-05-30 |
| AU2004206931A1 (en) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008116931A (ru) | Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей | |
| ES2393815T3 (es) | Agonistas opioides kappa para el tratamiento de síndrome del intestino irritable con diarrea predominante y alternante | |
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| WO1999047158A3 (en) | Therapeutic chemokine receptor antagonists | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| ZA200802811B (en) | Therapy for the treatment of disease | |
| JP2006501240A5 (ru) | ||
| ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
| NZ593467A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| GB2285219A (en) | Use of norastemizole for the treatment of allergic disorders | |
| Strober et al. | 26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry | |
| JP2016528171A5 (ru) | ||
| JPH08291077A (ja) | 骨萎縮改善剤 | |
| Wang et al. | Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| RU2013149635A (ru) | Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря | |
| RU2005135649A (ru) | Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| RU2003130641A (ru) | Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря | |
| JP2008106028A (ja) | 慢性疼痛の治療におけるフリバンセリンの使用 | |
| EP1535616A4 (en) | MEDICAMENT FOR SYNDROME OF INTEGRATION DYSFUNCTION | |
| CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance | |
| HU227813B1 (en) | Pharmaceutical composition for the treatment of psychosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110429 |